Motiwin Oral Suspension 5 mg/5 ml

Motiwin Oral Suspension is a gastrointestinal medication containing Domperidone Maleate (5 mg/5 ml) manufactured by Goodman Pharmaceuticals Ltd. Priced at ৳32.00 per unit, this oral suspension accelerates gastric emptying and alleviates nausea, vomiting, and dyspeptic symptoms.

Primarily prescribed for dyspeptic symptom complex, it addresses delayed stomach emptying, acid reflux, and epigastric discomfort. The drug inhibits dopamine receptors in the digestive tract, enhancing motility without crossing the blood-brain barrier significantly. Store below 30°C, protected from light/moisture.

Key Indications:

• Bloating, early satiety, and heartburn
• Nausea/vomiting from migraines or medications
• Parkinson’s disease-induced nausea
• Barium meal acceleration in radiology

Dosage varies by age and condition:
Adults: 10-20 mg (10-20 ml) every 6-8 hours pre-meal.
Children: 0.2-0.4 mg/kg body weight per dose. Maximum treatment duration: 12 weeks.

Common side effects (≤2%) include dry mouth, headaches, and mild diarrhea. Avoid with MAO inhibitors and opioids. Not recommended during pregnancy but safe for lactating mothers. Explore Domperidone alternatives under medical guidance.

Adults: 10-20 mg (10-20 ml suspension) every 6-8 hours before meals. Pediatric dose: 0.2-0.4 mg/kg body weight. Maximum 12 weeks for acute vomiting. Take oral suspension 15-30 minutes pre-meal and before bedtime.

Side-effects are rare; exceptionally some transient intestinal cramps have been reported. Extrapyramidal phenomena are rare in young children and exceptional in adults: they reverse spontaneously and completely as soon as the treatment is stopped. As the pituitary gland is located outside the blood-brain barrier, domperidone may induce an increase in the plasma prolactin level. In rare case this hyperprolactinaemia may give rise to neuroendocrinological phenomena such as galactorrhoea and gynaecomastia. When the blood-brain barrier is immature (as in infants) or impaired, the possible occurrence of neurological side-effects cannot be totally excluded. Rare allergic reactions, such as rash and urticaria, have also been reported.

Pregnancy safety unconfirmed; use not recommended. Low milk excretion during lactation poses minimal infant risk.

Dose adjustment needed for infants <1 year and hepatic patients. Monitor prolactin levels during prolonged therapy.

Pediatric: Neurological risk due to immature BBB. Hepatic/renal impairment: Reduce dose (70% hepatic metabolism). Elderly: Cardiac evaluation required.

Symptoms of overdosage may include drowsiness, disorientation and extrapyramidal reactions, especially in children. In case of overdosage, the administration of activated charcoal, and close observation of the patients are recommended. Anticholinergic, antiparkinson drugs or antihistamines with anticholinergic properties may be helpful in controlling the extrapyramidal reactions.